Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2572-2578

  Oyajobi, Babatunde O ^a   Anderson, Dirk M ^b   Traianedes, Kathy ^a   Williams, Paul J ^a   Yoneda, Toshiyuki ^a   Mundy, Gregory R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; FC RECEPTOR; HYBRID PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; HYPERCALCEMIA; LONG BONE; MALIGNANT NEOPLASTIC DISEASE; METAPHYSIS; MOUSE; NONHUMAN; NUDE MOUSE; OSTEOCLAST; PRIORITY JOURNAL; RAT; TISSUE CULTURE; TRABECULAR BONE; XENOGRAFT;

ANIMALS; BONE RESORPTION; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CHO CELLS; CRICETINAE; FEMALE; HUMANS; HYPERCALCEMIA; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LUNG NEOPLASMS; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; PREGNANCY; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SOLUBILITY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035866796     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
2. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
3. The role of receptor activator of nuclear factor-κb ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases
4. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption
5. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
6. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
7. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
8. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
9. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function
10. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts
11. RANK is essential for osteoclast and lymph node development
12. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
13. OPGL is a key regulator of osteoclastogenesis, lymph node development, and lymph node organogenesis
14. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells
15. 3 or parathyroid hormone
16. Osteoprotegerin. A novel secreted protein involved in the regulation of bone density
17. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification
18. Hypercalcemia of malignancy
19. Cancer and bone
20. Parathyroid hormone-related protein from a human lung cancer cell line
21. Parathyroid-hormone-like protein from human renal cell carcinoma cells: Structural and functional homology with parathyroid hormone
22. Hypercalcemia of malignancy: The central role of parathyroid hormone-related protein
23. Expression of receptor activator of nuclear factor κB ligand and M-CSF by human squamous cell carcinoma cells
24. Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
25. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand
26. The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-α enhance hypercalcemia in vivo and bone resorption in vitro
27. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
28. Assays for bone resorption and bone formation
29. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy
30. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
31. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL
32. Current and future directions in medical therapy: Hypercalcemia
33. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
34. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations
35. Effects of ibandronate in an in vivo model of multiple myeloma
36. Bisphosphonates may increase metastases to soft tissue sites in breast cancer and B-cell lymphoma
37. A soluble murine receptor activator of NF-κB-human immunoglobulin fusion protein (RANK.Fc) inhibits bone resorption in a routine model of human multiple myeloma bone disease
38. Administration of the TRANCE antagonist TR.Fc limits myeloma-induced bone destruction